![](/images/award_icon.png)
Development of Chol-Dsirna Polyplexes to Improve the Therapy of Breast CancerAward last edited on: 11/6/2019
Sponsored Program
STTRAwarding Agency
NIH : NCATSTotal Award Amount
$324,985Award Phase
1Solicitation Topic Code
-----Principal Investigator
Joseph Anthoney VetroCompany Information
Actorius Pharmaceuticals LLC
13031 Arbor Street
Omaha, NE 68144
Omaha, NE 68144
(402) 680-4792 |
N/A |
N/A |
Research Institution
----------
Phase I
Contract Number: ----------Start Date: ---- Completed: ----
Phase I year
2016Phase I Amount
$324,985Public Health Relevance Statement:
Public Health Relevance:
The proposed research is relevant to public health because the development of Chol-DsiRNA polyplexes is expected to improve the therapy of breast cancer and other solid tumors. Thus, the proposed research is relevant to the part of NIH's mission to foster the application of innovative research strategies to ultimately protect and improve health.
Project Terms:
4T1; Age; Animal Model; Breast cancer metastasis; Breast Cancer therapy; cancer therapy; cancer type; Cells; Cessation of life; Cholesterol; Clinic; clinical application; Complex; copolymer; Data; Development; Diffuse; Disease; Distal; Dose; Drops; Drug Kinetics; effective therapy; Epithelial Cells; expectation; Female; Filtration; Fostering; Goals; Health; Human; improved; Inbred BALB C Mice; innovation; Investigational Drugs; Investigational New Drug Application; jejunum; Kidney; Liver; Lysine; male; malignant breast neoplasm; Mammary Neoplasms; Maximum Tolerated Dose; MDA MB 231; meetings; Messenger RNA; Metastatic breast cancer; MicroRNAs; Mission; Modification; mouse model; Mus; Neoplasm Metastasis; nuclease; Patients; Phase; Phase I Clinical Trials; Polyethylene Glycols; Primary Neoplasm; Process; Proteins; Public Health; public health relevance; Research; Resistance; RNA Interference; Serum; Small Business Technology Transfer Research; Small Interfering RNA; Solid Neoplasm; Staging; Survival Rate; Therapeutic Effect; Toxic effect; treatment strategy; tumor; Woman; Work
Phase II
Contract Number: ----------Start Date: ---- Completed: ----